Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Blarcamesine - Anavex Life Sciences

Next Previous
X
Search
Drug Profile

Blarcamesine - Anavex Life Sciences

Alternative Names: AE-37 hydrochloride; ANA001-HCl; ANAVEX 2-73; Blarcamesine hydrochloride - Anavex Life Sciences

Latest Information Update: 01 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anavex Life Sciences
  • Developer Anavex Life Sciences; The Michael J. Fox Foundation for Parkinsons Research
  • Class Antidementias; Antidepressants; Antiepileptic drugs; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Biphenyl compounds; Dimethylamines; Furans; Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Muscarinic receptor modulators; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome; Rett syndrome; Infantile spasms
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Alzheimer's disease
  • Phase II/III Fragile X syndrome; Rett syndrome; Unspecified
  • Phase II Parkinson's disease
  • Phase I Angelman syndrome; Infantile spasms
  • Discontinued Amyotrophic lateral sclerosis; Anxiety disorders; Autistic disorder; Cognition disorders; Multiple sclerosis; Stroke

Most Recent Events

  • 30 Jul 2024 Anavex Life Sciences plans a clinical trial for Fragile X syndrome
  • 28 Jul 2024 Updated efficacy and adverse event data from a phase IIb/III trial in Alzheimer's disease released by Anavex Life Sciences
  • 14 Jun 2024 Anavex Life Sciences completes a phase IIb/III trial in ATTENTION-AD trial for Alzheimer’s disease in Australia, Canada, Germany, Netherlands, United Kingdom (PO) (NCT04314934)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top